Cleerly Makes Debut at RSNA 2024, Showcasing AI-Enabled Innovations in Cardiovascular Imaging
Join Cleerly Leadership for Live Demonstrations on Advanced Imaging Solutions for Personalized Heart Disease Care
Learn About Cleerly's Technology at Booth 3905
Cleerly software is an AI-enabled digital care platform to support physicians to precisely identify, and define heart disease by analyzing non-invasive CCTA images. Cleerly supports precision diagnostics through sub-millimeter quantification and characterization of atherosclerosis, or plaque build-up in the heart arteries, so that healthcare professionals can provide personalized treatment plans for patients across the care continuum.
Cleerly's AI-Quantitative Coronary CT (AI-QCT) technology, Cleerly Labs, in several studies comparing it with invasive gold standards, has been demonstrated to be highly accurate in the assessment of the presence, extent, and composition of coronary atherosclerotic plaque and similar to consensus readings of Level 3 Expert Physician Readers. Cleerly ISCHEMIA, an additional AI-enabled product, has also been proven to demonstrate high diagnostic performance compared to invasive fractional flow reserve (FFR) and higher performance than such legacy tests as nuclear SPECT imaging and FFRCT.
Meet Cleerly Leadership
Cleerly invites attendees to meet the visionary leaders of Cleerly at the RNSA conference on
Recent Milestones in Medicare and Insurance Coverage
Last month, in a significant advancement for AI-driven technologies, five Medicare Administrative Contractors officially approved AI-QCT scans for Medicare recipients exhibiting stable and acute symptoms suspicious of coronary artery disease. The new coverage took effect on
Additionally, the American Medical Association recently approved a permanent CPT Category I code for Cleerly's AI-QCT advanced plaque analyses, effective
Stop by and learn more about Cleerly at Booth 3905 located in South Hall A, Level 3 or, to schedule a meeting with Cleerly leadership, please visit this link.
About Cleerly®
Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Cleerly's approach is grounded in science, based on millions of medical images. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: www.cleerlyhealth.com.
Click here for more details about our booth at: https://rsna2024.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=01923946.
View original content:https://www.prnewswire.com/news-releases/cleerly-makes-debut-at-rsna-2024-showcasing-ai-enabled-innovations-in-cardiovascular-imaging-302316179.html
SOURCE Map Your Show
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- What To Expect After Your Doctor Finds a Lung Nodule
- Stabilization Notice - Pre Stab Notice NEXANS
- Fibocom Launches RU311 5G RedCap Module Series for Streamlined 5G Upgrades in Mid-Tier IoT
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share